Meet the healthcare futurist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Imran Kausar, Founder of DeepHealth Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Imran, covering: His unusual blend of experience led to a road into big pharma... Switching the security of Big Pharma to join an exciting, scrappy, start-up biotech... before an exit to Roche Being part of the gene therapies evolution with an innovative biotech that later became Novartis Gene Therapies His views on the thorny issue of CGT products' price (and value) Opting to start his own business aimed at supporting the future of healthcare Imran Kausar is a visionary healthcare and life sciences leader, blending medical expertise with strategic foresight. A medical doctor by training, Imran specialized in anesthesia and critical care before transitioning to the pharmaceutical industry. Having launched five rare disease medicines and spearheaded innovative work in gene therapies like Zolgensma and Luxturna across Europe, Imran has earned his reputation as a trailblazer in the industry. As the founder of DeepHealth Consulting, Imran leads the flagship program DeepHealth Futures, which equips life sciences teams to navigate the transformative forces of AI, longevity science, and precision medicine.With nearly two decades of experience in medicine, medical affairs, and general management, Imran’s career spans the cutting edge of rare diseases, antisense oligonucleotides, and healthcare transformation.    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.